Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity

Anthracyclines such as doxorubicin are highly effective chemotherapy agents used to treat many common malignancies. However, their use is limited by cardiotoxicity. We previously identified visnagin as protecting against doxorubicin toxicity in cardiac but not tumor cells. In this study, we sought t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JCI Insight
Prif Awduron: Asnani, Aarti, Zheng, Bahoui, Liu, Yan, Wang, You, Chen, Howard H., Vohra, Anita, Chi, An, Cornella-Taracido, Ivan, Wang, Huijun, Johns, Douglas G., Sosnovik, David E., Peterson, Randall T.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2018
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5821184/
https://ncbi.nlm.nih.gov/pubmed/29321375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.96753
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg